Veracyte's $150M Quarter: Prosigna and TrueMRD Could Change the Growth Story

Veracyte's core business stayed strong while two new tests widened the opportunity

Veracyte posted $150.3 million of total revenue and $145.7 million of testing revenue, while also launching two tests that could pull a larger share of cancer-care spending into the company. Prosigna moves Veracyte into treatment decision-making in early-stage HR+ breast cancer, and TrueMRD opens a different part of the care continuum with recurrence monitoring following definitive treatment with curative intent in patients with MIBC.

Management described Q2 as a milestone quarter and said launch interest has been strong, including engagement from more than 100 institutions. The near-term question is whether these products are a modest add-on or a meaningful step change in Veracyte's long-term growth profile.

That clinical role matters because the addressable population is large and the unmet need is real. Management says Veracyte believes Prosigna can be used across the full ER-positive, HER2-negative breast cancer population and is expanding its sales and workflow support to capture demand. After the OPTIMA readout, the company also reported launch interest has been strong.

The bullish case is straightforward: Prosigna has a defined clinical use, a large patient population, and early commercial traction. The cautious read is simpler too: early interest is not the same as durable workflow adoption or reimbursement stability. The next proof point is whether orders and use persist after the initial launch phase.

TrueMRD's appeal is the repeat-use model, not just the launch itself

TrueMRD matters because it can change the shape of Veracyte's revenue, not simply add another one-time diagnostic sale. The CMS decision was the first Medicare coverage decision for the TrueMRD platform, and coverage in MIBC creates the possibility of serial testing after definitive treatment rather than a single-use order.

The platform logic also helps explain the longer-term upside. TrueMRD is a whole-genome, tumor-informed test that builds a personalized signature that is unique to each patient's cancer and then uses that profile to monitor cancer patients at regular intervals. Management has said the Medicare win is a step toward expanding the platform across multiple cancer types over time.

For now, the opportunity is still narrow. One covered indication is not the same as a broad reimbursement framework, and earlier detection only becomes a durable franchise if it fits cleanly into post-treatment care. Still, as an optionality bet, TrueMRD deserves attention because it could deepen patient monitoring over time rather than serving only a single decision point.

The core business still funds the next leg of growth

This quarter matters because Veracyte did not need the new launches to carry the results. The company reported total revenue up 15%, testing revenue up 19%, and $44.0 million in adjusted EBITDA. That gives investors a clearer picture: the existing franchises are still producing growth and margin while management builds the next layer of product breadth.

What could change the stock story is proof that these launches can be stitched into one broader business. Prosigna gives Veracyte a seat at the treatment-decision table in early-stage HR+ breast cancer. TrueMRD gives it a repeat-use monitoring model, starting with recurrence monitoring following definitive treatment with curative intent in patients with MIBC. If those threads keep gaining traction, the market may view Veracyte as more than a collection of isolated tests.

What would confirm the thesis

• The core business continues to grow and absorb lowered full-year test volume expectations in Decipher.
• Prosigna converts early interest into sustained ordering and workflow adoption.
• TrueMRD expands beyond its first covered indication while keeping reimbursement and clinical demand moving forward.

What could slow the rerating

If the core weakens faster than the new tests scale, or if Prosigna and TrueMRD remain interesting but isolated products, investors are more likely to keep valuing Veracyte as a portfolio of tests rather than a broader cancer-monitoring platform.